DEAFLOR 180 CAPSULES

Descriptive sheet

Deaflor

A dietary supplement based on probiotics and prebiotics. It promotes the rebalancing of intestinal flora, helps fight bacterial infections, and resolve problems related to the presence of pathogens.
Probiotics are valuable allies of the body in restoring the physiological intestinal flora that has been damaged or compromised, even following antibiotic therapy.
- They inhibit the growth and proliferation of pathogenic anaerobic bacteria associated with vaginosis, acting as their antagonists;
- thanks to the co-aggregation process, they neutralize the ability of pathogenic bacteria to adhere to tissues, damaging them, and prevent them from carrying out actions harmful to the organism;
- they have an important role in the stimulation and production of lactobacilli;
- they help resolve diarrheal episodes more quickly;
- they have an inhibitory effect on the adhesion capacity of E.Coli, E.Faecalis, Candida Albicans and many other germs to the mucosa;
- they counteract the accumulation of oxidative waste, promoting cell renewal;
- bifidobacteria improve calcium metabolism and help prevent osteoporosis and fight excess cholesterol.

It does not contain gluten.

Ingredients
FOS (Fructo-oligosaccharides), Klamath algae, Lactobacillus rhamnosus, Lactobacillus acidophilus DDS-1, Bifidobacterium bifidum, Lactobacillus bulgaricus DDS-14.

How to use
It is recommended to take three capsules a day, with meals.

Warnings
Keep out of reach of children. Do not exceed the recommended dose. Supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle. Pregnant or breastfeeding women and children are advised to consult a doctor.

Conservation
Store the product at a temperature between 10°C and 20°C.

Format
Pack of 180 capsules of 425 mg.

Bibliography :
Lactobacillus rhamnosus
- Salminen, Seppo; Lee, Yuan C., Handbook of probiotics and prebiotics (in en), Chichester, John Wiley & Sons, 2009, pp. 596. ISBN 0-470-13544-1
- Philip D. Marsh BSc PhD, Oral Microbiology (in en), Edinburgh, Churchill Livingstone, 2009, 35, 112. ISBN 0-443-10144-2
- Handbook of Fermented Functional Foods, Second Edition (Functional Foods and Nutraceuticals) (in en), Washington, DC, Taylor & Francis, 2008, pp. 581. ISBN 1-4200-5326-4
- Preedy, Victor R.; Watson, Ronald R., Bioactive Foods in Promoting Health: Probiotics and Prebiotics (in en), Boston, Academic Press, 2010. ISBN 0-12-374938-7
- Ercolini, Danilo; Cocolin, Luca, Molecular techniques in the microbial ecology of fermented foods (in en), Berlin, Springer, 2008, pp. 280. ISBN 0-387-74519-X
- Salminen, Seppo; Wolfgang Kneifel, Probiotics and Health Claims (in en), Wiley-Blackwell, 2011, pp. 340. ISBN 1-4051-9491-X
- Min-tze Liong, Probiotics: Biology, Genetics and Health Aspects (Microbiology Monographs) (in en), Berlin, Springer, 2011, pp. 327. ISBN 3-642-20837-1
- Mohamed Ahmedna; Ipek Goktepe; Vijay K. Juneja, Probiotics in Food Safety and Human Health (in en), Boca Raton, CRC, 2005, pp. 463. ISBN 1-57444-514-6
- Terry Finocchiaro; Susan Sungsoo Cho, Handbook of Prebiotics and Probiotics Ingredients: Health Benefits and Food Applications (in en), Boca Raton, CRC, 2009, pp. 435. ISBN 1-4200-6213-1
- Prebiotics and Probiotics Science and Technology , Springer, 12 August 2009, 986–. ISBN 978-0-387-79057-2
— Biotechnology of Lactic Acid Bacteria: Novel Applications , John Wiley & Sons, April 6, 2010, 346–. ISBN 978-0-8138-1583-1

Regarding the use of Lactobacillus rhamnosus in combating Crohn's disease, see
- Shen, J., H.Z. Ran; MH. Yin; TX. Zhou; DS. Xiao (February 2009). Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn's disease. . Intern Med J 39(2):103-9. DOI:10.1111/j.1445-5994.2008.01791.x. PMID 19220543.
- Bousvaros, A., S. Guandalini; RN. Baldassano; C. Botelho; J. Evans; GD. Ferries; B. Goldin; L. Hartigan; S. Kugathasan; J. Levy; KF. Murray (September 2005). A randomized, doubleblind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. . Inflamm Bowel Dis 11(9):833–9. PMID 16116318.
- Braat, H., J. van den Brande; E. van Tol; D. Hommes; M. Peppelenbosch; S. van Deventer (December 2004). Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. . Am J Clin Nutr 80(6):1618-25. PMID 15585777.
- Prantera, C., ML. Scribano (September 2002). i>Probiotics and Crohn's disease.. Dig Liver Dis34 Suppl 2: S66-7. PMID 12408444

For use against ulcerative colitis , see
- Bränning, CE., ME. Nyman (January 2011). Malt in combination with Lactobacillus rhamnosus increases concentrations of butyric acid in the distal colon and serum in rats compared with other barley products but decreases viable counts of cecal bifidobacteria. . J Nutr 141(1):101-7. DOI:10.3945/jn.110.122226. PMID 21106924.
- Do, VT., BG. Baird; DR. Kockler (March 2010). Probiotics for maintaining remission of ulcerative colitis in adults. . Ann Pharmacother 44(3):565-71. DOI:10.1345/aph.1M498. PMID 20124461.
- Heilpern, D., A. Szilagyi (September 2008). Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. . Rev Recent Clin Trials 3 (3): 167-84. PMID 18782075.
- Lorea Baroja, M., PV. Kirjavainen; S. Hekmat; G. Reid (September 2007). Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. . Clin Exp Immunol 149(3):470-9. DOI:10.1111/j.1365-2249.2007.03434.x. PMID 17590176.
- Gosselink, MP., WR. Schouten; LM. van Lieshout; WC. Hop; JD. Laman; JG. Ruseler-van Embden (June 2004). Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. . Dis Colon Rectum 47 (6): 876- 84. DOI:10.1007/s10350-004-0525-z. PMID 15108026.